Welcome to our dedicated page for Harrow Health news (Ticker: HROW), a resource for investors and traders seeking the latest updates and insights on Harrow Health stock.
Harrow, Inc. (Nasdaq: HROW) is an ophthalmic-focused pharmaceutical company that regularly issues news and updates related to its portfolio of eye-care products, development programs, and corporate activities. The company describes itself as a leading provider of ophthalmic disease management solutions in North America, with products that address conditions such as dry eye disease, wet age-related macular degeneration, cataracts, refractive errors, glaucoma, ocular surface conditions, and retina diseases.
News about Harrow commonly covers financial results and investor communications, including quarterly earnings releases, letters to stockholders, and conference call announcements. The company also announces participation in investor conferences and Investor & Analyst Day events, where it provides overviews of its commercial portfolio, pipeline, and long-term vision.
Another key theme in Harrow’s news flow is business development and pipeline progress. Recent press releases have described the agreement to acquire, and subsequent closing of the acquisition of, Melt Pharmaceuticals, Inc., a clinical-stage company developing non-opioid, non-IV sedation therapies such as MELT-300 and MELT-210. Harrow has used these announcements to explain the strategic rationale for expanding into procedural sedation and to outline regulatory and development milestones for these product candidates.
Harrow’s news also highlights access and affordability initiatives, such as the launch of the VEVYE Access for All (VAFA) program for VEVYE (cyclosporine ophthalmic solution) 0.1% and the broader Harrow Access for All (HAFA) program, which is intended to extend a unified access model across its branded, authorized generics, and compounded ophthalmic medications. Additional releases address leadership changes at ImprimisRx, debt offerings and related credit facilities, and other corporate matters.
Investors and eyecare professionals reviewing Harrow’s news page can expect updates on earnings, capital markets transactions, acquisitions, development milestones for ophthalmic and procedural sedation candidates, and initiatives aimed at improving patient access to the company’s ophthalmic therapies.
Harrow Health (NASDAQ: HROW) will release its second quarter 2020 financial results on August 10, 2020, following the market close. A conference call is scheduled for 5:00 PM EDT to discuss these results and recent business developments. The press release will also include a link to the second quarter Letter to Stockholders, available on the Investor Relations website. A replay of the conference call will be accessible until September 10, 2020, with a webcast replay available until November 10, 2020.
Harrow Health (NASDAQ: HROW) announced positive findings from a randomized eye study conducted by its subsidiary ImprimisRx. The study compared patient outcomes using a combination eye drop versus individual drops post-cataract surgery. Results showed the combination drop, which includes prednisolone acetate, gatifloxacin, and bromfenac sodium, demonstrated similar health outcomes with unanimous patient preference for ease of use. The study, published in Clinical Ophthalmology, highlights ImprimisRx's commitment to improving patient compliance and satisfaction with ocular treatments.
Harrow Health, Inc. (HROW) announced that Florida's optometrists can now prescribe its Klarity-C formulation, a preservative-free 0.1% cyclosporine emulsion, following recent updates to the state’s Formulary of Topical Ocular Pharmaceutical Agents. This product has already been prescribed across all 50 states. ImprimisRx, a subsidiary of Harrow, emphasizes the affordability and accessibility of its formulations without the complexities of prior authorizations or co-pays. Klarity-C has gained recognition at the ASCRS Annual Meeting for its efficacy in treating dry eye conditions.
Harrow Health, Inc. (NASDAQ: HROW) announced its first quarter 2020 results, highlighting its optimistic outlook as segments of the economy recover. CEO Mark L. Baum expressed confidence in the ImprimisRx team's ability to support physicians and improve health outcomes. The company has seen orders resume as customers re-open. Upcoming catalysts and developments are discussed in the Letter to Stockholders. A conference call is scheduled for today at 5:00 p.m. EDT for investors and analysts to engage with management.
Summary not available.